Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TNG348

Small molecule · Inhibitor of ubiquitin specific peptidase 1 (USP1) · developed by Tango Therapeutics

Phase 1/2 Most advanced trial (none active)
TNGX Developer
1 Registered trials

What is TNG348?

TNG348 is an orally bioavailable small molecule that allosterically binds and inhibits the deubiquitinating enzyme USP1, blocking its deubiquitinating activity. USP1 supports DNA repair through the Fanconi anemia complex and translesion synthesis, and TNG348 is being studied in breast, ovarian, pancreatic and prostate cancers, including BRCA-mutated and HRD-positive tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
ubiquitin specific peptidase 1 (USP1)
Mechanism
Inhibitor of ubiquitin specific peptidase 1 (USP1)
Pathways
DNA damage repair, Fanconi anemia pathway, translesion synthesis, replication fork stability
Therapy area
Oncology
Developer
Tango Therapeutics, Inc. (TNGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06065059 Phase 1/2 Breast Cancer Terminated TNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

BRCA-Associated Breast CarcinomaBRCA-Mutated Ovarian CarcinomaBRCA1 MutationBreast CancerHRD Positive Advanced Ovarian CancerOvarian CancerPancreas CancerProstate Cancer

Other drugs acting on USP1

More from Tango Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.

Follow TNGX, the company behind TNG348

See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TNGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.